Articles tagged "Kidney transplantation"

2018 American Transplant Congress
Determinants of Delays and Reduced Rates of Waitlisting and Kidney Transplant among American Indians
M. Keddis, M. Ilyas, N. Zhang, H. Khamash, S. Leischow, A. Sharma, R. Heilman.
Mayo Clinic, Phoenix, AZ.
Introduction: American Indian (AI) patients experience delays in every step of the kidney transplant (KTx) evaluation. Our objective is to determine the contribution of co-morbid…
2018 American Transplant Congress
T Cell Immunomonitoring Including Donor Specific Treg Expansion Prospectively Predicts Renal Allograft Tolerance Induced by Transient Mixed Chimerism
K. Hotta, T. Oura, A. Dehnadi, K. Huh, M. Matsunami, H. Sasaki, G. Benichou, J. Madsen, A. Cosimi, T. Kawai.
Center for Transplant Science, Massachusetts General Hospital, Boston, MA.
Background: Successful induction of allograft tolerance in MHC-mismatched kidney transplantation has been achieved after induction of transient chimerism in both nonhuman primates (NHP) and humans.…
2018 American Transplant Congress
“I'll Be Back”: Increasing Readmission Rates in the Era of the New Kidney Allocation System
N. Pilch, C. Mardis, H. Meadows, J. Fleming, N. Patel, C. Perez, P. Baliga, D. Dubay, V. Rohan, V. Rao, D. Taber.
MUSC, Charleston.
Background: National analysis of the impact of the new KAS has indicated an increase in DGF rates, total inpatient hospital costs & 30 day readmission…
2018 American Transplant Congress
Short-Term Outcome Prediction Model in Deceased Donor Kidney Transplant Recipients
K. Archer,¹ Y. Zhang,¹ S. Bontha,² E. Akalin,³ L. Gallon,⁴ D. Maluf,² V. Mas.²
¹OSU, Columbus; ²UVA, Charlottesville; ³Montefiore, New York; ⁴NWU, Chicago.
Background: Lack of accurate outcome prediction models may be a reason for the increase in organ discard rate that further burdens the growing kidney transplant…
2018 American Transplant Congress
Preemptive Rituximab in Focal and Segmental Glomerulosclerosis Patients at Risk for Recurrence after Transplantation
P. Auñon,¹ N. Polanco,¹ M. Perez,² E. Rodrigo,³ A. Sancho,⁴ J. Pascual,² A. Andres,¹ M. Praga.¹
¹Nephrology Department, Hospital Doce de Octubre, Madrid, Spain; ²Nephrology Department, Hospital del Mar, Barcelona, Spain; ³Nephrology Department, Hospital Marques de Valdecilla, Santander, Spain; ⁴Nephrology Department, Hospital Doctor Peset, Valencia, Spain.
INTRODUCTIONRecurrence of focal and segmental glomerulosclerosis (FSGS) after renal transplantation is a characteristic complication of the disease that occurs in one third of the cases.…
2018 American Transplant Congress
Thymoglobulin Dose and Effect on Short-Term Kidney Transplant Outcomes
P. Sood, W. Christine, R. Mehta, A. Tevar, C. Puttarajappa, K. Schonder, K. Shimko, S. Hariharan.
University of Pitstburgh Medical Center, Pittsburgh.
Thymoglobulin is a commonly used induction agent for kidney transplantation. Optimal dosing for thymoglobulin is not well defined, and weight based dosing is often used.…
2018 American Transplant Congress
Graft Failure in Recurrent IgA Nephropathy Following Living Kidney Transplantation: Predictive Factors Analysis of 102 Biopsies
J. Zhang, J. Qiu, G. Chen, C. Wang, L. Chen.
Organ Transplant Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Aim To investigate the predictive factors related to graft failure in recurrentIgA nephropathy (IgAN) following living kidney transplantation. Methods We identified a series of 102…
2018 American Transplant Congress
The Incidence and Risk Factors for Non – Adherence to Medical Treatment among Patients after Kidney Transplantation
T. Mashraki,^1,2,3 B. Rozen-Zvi,^1,4 E. Mor,^2,4 A. Yussim,^1,2 C. Avry,^1,4 R. Rahamimov.^1,2,3
¹Nephrology and Hypertension, Rabin Medical Center, Petach Tikva, Israel; ²Transplantation, Rabin Medical Center, Petach Tikva, Israel; ³Faculty of Health Science, Ariel University Center of Samaria, Ariel, Israel; ⁴Sackler Faculty of Medicine, Tel- Aviv University, Tel- Aviv, Israel.
Background: Nonadherence to medical treatment is an important risk factor for acute rejection and graft loss. In this study we sought to determine the prevalence…
2018 American Transplant Congress
Transplantation of Very Small Pediatric En Bloc Renal Allografts from Donors Less Than 8 Months of Age Have Similar Outcomes to Donors More Than 8 Months
S. Aquil,^1,2,3 N. Mitrou,^1,3 V. McAlister,^1,2,3 A. Sener,^1,2,3 P. Luke.^1,2,3
¹Departments of Surgery and Transplant, London Health Sciences Centre, University Hospital, London, ON, Canada; ²Microbiology and Immunology and Matthew Mailing Center for Transplant Studies, London Health Sciences Centre, University Hospital, London, ON, Canada; ³Departments of Surgery and Transplant, Western University, London, ON, Canada.
Purpose: Few programs use kidneys from donors with body weight (BW) less than 10 kg or less than 8 months of age, for fear of…
2018 American Transplant Congress
A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients
G. Burckart,¹ M. Cavaillé-Coll,² A. Duong,³ L. Hothem,⁴ R. Albrecht.²
¹Office of Clinical Pharmacology, Office of Translational Science, CDER, US Food and Drug Administration, Silver Spring, MD; ²Division of Transplant and Opthalmology Products, Office of New Drugs, CDER, US Food and Drug Administration, Silver Spring, MD; ³Tauro University, New York, NY; ⁴University of North Carolina, Chapel Hill, NC.
The development of drugs for organ transplantation spanned the time before and after pediatric regulatory requirements under the Best Pharmaceuticals for Children Act (BPCA) and…